AMLX logo

Amylyx Pharmaceuticals Inc. (AMLX)

$30.21

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AMLX

Market cap

$3.88B

EPS

-1.42

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-0.080021

Price on AMLX

Previous close

$29.50

Today's open

$29.85

Day's range

$28.76 - $30.32

52 week range

$10.83 - $41.14

Profile about AMLX

CEO

Joshua Cohen

Employees

136

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

128562904

Issue type

Common Stock

AMLX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief Commercial Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Jacob Ormes - TD Securities Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Geoffrey Meacham - Citigroup Inc. Exchange Research Marc Goodman - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Dina Ramadane - BofA Securities, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.

news source

Seeking Alpha • Nov 6, 2026

news preview

Amylyx Pharmaceuticals Q3 Earnings Call Highlights

Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results.

news source

MarketBeat • Nov 5, 2026

news preview

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.

news source

Business Wire • Nov 5, 2026

news preview

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.

news source

Business Wire • Nov 4, 2026

news preview

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.

news source

Business Wire • Nov 3, 2026

news preview

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.

news source

Business Wire • Nov 2, 2026

news preview

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

news source

Schaeffers Research • Oct 12, 2026

news preview

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.

news source

Business Wire • Oct 6, 2026

news preview

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.

news source

MarketBeat • Oct 3, 2026

news preview

10 Stocks With Massive Short Squeeze Potential

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

news source

Schaeffers Research • Oct 1, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Amylyx Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Amylyx Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AMLX on M1